用于治疗骨髓纤维化的小分子JAK抑制剂及其专利研究

Small Molecule JAK Inhibitors for the Treatment of Myelofibrosis and Its Patent Research

该研究梳理了全球已获批上市和正在研发中的用于治疗骨髓纤维化的小分子JAK抑制剂药物品种情况,对其中3个重点药物磷酸芦可替尼、盐酸菲卓替尼、枸橼酸帕克替尼的研发进展,以及涉及其化合物、晶型、盐型、工艺、药物制剂、药物组合物、新用途和衍生物等不同技术主题的已公开专利进行研究和分析,以期为医药企业在进行有关药物的立项与开发、新的专利挖掘、专利保护及专利布局时,提供有效的产品信息和专利信息等参考。

Three small molecule JAK inhibitors,namely ruxolitinib phosphate,fedratinib hydrochloride,and pacritinib citrate,for the treatment of myelofibrosis have been marketed worldwide.Their research progress and the published patents on chemical compound,crystalline form,salt form,process,formulation,drug combination,new use,and product derivatives,as well as the compounds in pharmaceutical research are unscrambled and researched in this paper.It is hoped to provide patent information and reference for Chinese pharmaceutical companies conducting project establishment and development,new patent mining,patent protection,and patent layout.